Zobrazeno 1 - 10
of 151
pro vyhledávání: ''
Autor:
Xiaoqin Jia, Jieping Chen, Mei Kuang, Yu Hou, Chengfang Zhou, Weiru Wu, Zhe Chen, Zhilong Liu, Yuanyuan Liu, Le Ma, Zhigang Li
Publikováno v:
Leukemia. 36:834-846
FZR1 has been implicated as a master regulator of the cell cycle and quiescence, but its roles and molecular mechanisms in the pathogenesis of severe aplastic anemia (SAA) are unclear. Here, we report that FZR1 is downregulated in SAA HSCs compared w
Autor:
Charles S. Kuzma, Harry P. Erba, Mark R. Litzow, Steven Coutre, Scott E. Smith, Richard Stone, Amy S. Ruppert, Allison M Booth, Nancy L. Bartlett, Jeremy S. Abramson, John C. Byrd, Jennifer A. Woyach, Jennifer R. Brown, Richard F. Little, Richard A. Larson, Sumithra J. Mandrekar, Wei Ding, Sreenivasa Nattam, Carolyn Owen, Danielle M. Brander
Publikováno v:
Leukemia
Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) compar
Autor:
Banumathi Tamilselvan, Zachary Jackson, Susan Pereira Ribeiro, Jill S. Barnholtz-Sloan, Jaroslaw P. Maciejewski, David N. Wald, Kalpana Gupta, Ashish Sharma, Xuan Xu, Rafick-Pierre Sekaly, Robert Schauner, Anne Roe, Samuel Li, Robert S. Balderas, Tae Hyun Hwang, Lindsay Stetson, Slim Fourati, Marcos de Lima, Thomas LaFramboise, Dheepa Balasubramanian, Yogen Saunthararajah, Tammy Stefan
Publikováno v:
Leukemia
The prognosis of most patients with AML is poor due to frequent disease relapse. The cause of relapse is thought to be from the persistence of leukemia initiating cells (LIC's) following treatment. Here we assessed RNA based changes in LICs from matc
Autor:
Angela Dispenzieri, Giampaolo Merlini, Arun Kumar, Ashutosh D. Wechalekar, Heather Landau, Vaishali Sanchorawala, Kihyun Kim, Efstathios Kastritis, Raymond L. Comenzo, Guohui Liu, Deborah Berg, Fiona Kwok, Stefan Schönland, Douglas V. Faller, Kenshi Suzuki
Publikováno v:
Leukemia
In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1–2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, d
Autor:
Wolf-Karsten Hofmann, Arwin Mehralivand, Laurenz Steiner, Nanni Schmitt, Ahmed Jawhar, Cleo-Aron Weis, Stefanie Uhlig, Justine Danner, Vladimir Riabov, Ali Darwich, Qingyu Xu, Julia Obländer, Eva Altrock, Tobias Boch, Nadine Weimer, Florian Nolte, Antje Knaflic, Mohamad Jawhar, Alexander Streuer, Verena Haselmann, Daniel Nowak, Johann-Christoph Jann, Verena Nowak, Alexander Marx, Georgia Metzgeroth, Johanna Flach, Iris Palme
Publikováno v:
Leukemia
Preclinical research of myelodysplastic syndromes (MDSs) is hampered by a lack of feasible disease models. Previously, we have established a robust patient-derived xenograft (PDX) model for MDS. Here we demonstrate for the first time that this model
Autor:
Zeev Estrov, Prithviraj Bose, Varsha Gandhi, Jan A. Burger, Xuemei Wang, Naveen Garg, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Philip A. Thompson, Ana Ayala, Hagop M. Kantarjian, Koji Sasaki, Keyur P. Patel, Tapan M. Kadia, Alessandra Ferrajoli, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Koichi Takahashi, Marina Konopleva, Wanda Lopez, Michael J. Keating, Wei Wang, William G. Wierda, Nitin Jain, Jeffrey L. Jorgensen, William Plunkett, Sa Wang
Publikováno v:
Leukemia. 35:3421-3429
Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mut
Autor:
Courtney D. DiNardo, Veronica A Guerra, Nicholas J. Short, Elias Jabbour, Zeev Estrov, Guillermo Montalban-Bravo, Danielle Hammond, Kiran Naqvi, Sherry Pierce, Naveen Pemmaraju, Hagop M. Kantarjian, Jorge Ramos-Perez, Gautam Borthakur, Rashmi Kanagal-Shamanna, Koji Sasaki, Marina Konopleva, Tapan M. Kadia, Naval Daver, Farhad Ravandi, Guillermo Garcia-Manero
Publikováno v:
Leukemia. 35:1494-1499
Autor:
Ying Huang, James L. Fisher, Erin M. Bertino, Samantha Jaglowski, Kami J. Maddocks, Seema A. Bhat, John C. Byrd, Amy S. Ruppert, David A. Bond, Michael R. Grever, Dwight H. Owen, Jennifer A. Woyach, Kerry A. Rogers
Publikováno v:
Leukemia
7511 Background: Patients (pts) with chronic lymphocytic leukemia (CLL) suffer morbidity and mortality from CLL and increased risk for second primary neoplasia (SPN). BTK inhibitors (BTKi) are highly effective for the treatment (tx) of CLL and are as
Publikováno v:
Leukemia. 35:906-909
Autor:
Bonnie K. Arendt, S V Rajkumar, Shaji Kumar, David L. Murray, Dirk R. Larson, Robert A. Kyle, Surendra Dasari, Angela Dispenzieri, Maria Willrcih, Taxiarchis Kourelis
Publikováno v:
Leukemia
Our group previously demonstrated that M-protein light chain (LC) glycosylation can be detected on routine MASS-FIX testing. Glycosylation is increased in patients with immunoglobulin light chain amyloidosis (AL) and rarely changes over the course of